Additional file 1: Table S1. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Yamanaka, Hisashi; Tanaka, Yoshiya; Takeuchi, Tsutomu; Sugiyama, Naonobu; Yuasa, Hirotoshi; Toyoizumi, Shigeyuki; Morishima, Yosuke; Hirose, Tomohiro; Zwillich, Samuel

doi:10.6084/m9.figshare.c.3615428_D1.v1

13075_2016_932_MOESM1_ESM.pdf (14.71 kB)

Additional file 1: Table S1. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

journal contribution

posted on 2016-01-28, 05:00 authored by Hisashi Yamanaka, Yoshiya Tanaka, Tsutomu Takeuchi, Naonobu Sugiyama, Hirotoshi Yuasa, Shigeyuki Toyoizumi, Yosuke Morishima, Tomohiro Hirose, Samuel Zwillich

Summary of seven patient deaths. (PDF 14 kb)

Funding

Pfizer (US)

History

Usage metrics

Keywords

Tofacitinib Japanese Rheumatoid arthritis Long-term extension

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 1: Table S1. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Funding

Pfizer (US)

History

Usage metrics

Categories

Keywords

Licence

Exports